Market Size (2015)
2015
$32.21B
Vertical: HealthcareBase Year: 201711 Sections
Market Size (2015)
2015
$32.21B
Projected (2023)
2023
$41.12B
CAGR (2015–2023)
3.1%
3.1%Key Players
107+
Hypertension also called as high blood pressure, is a chronic condition which occurs when the blood pressure in the arteries is continuously elevated. Long-term high blood pressure is a major risk factor for coronary artery disease, stroke, heart failure, vision loss, atrial fibrillation, peripheral vascular disease, chronic kidney disease, and dementia, among others. High blood pressure is classified as either primary hypertension and secondary hypertension. The increasing prevalence of hypertension is expected to contribute to the growth of the market over the forecast period.
The global antihypertensive drugs market is expected to reach USD 41,123.2 million by 2023 from USD 34,843.6 million in 2017 and is expected to register a CAGR of 2.67% during the forecast period from 2018 to 2023. In 2017, the market was led by the Americas with a 36.6% share, followed by Europe and Asia-Pacific with shares of 28.2% and 22.8%%, respectively.
The market has been segmented based on therapeutic class, type, distribution channel, and region.
The global antihypertensive drugs market on the basis of therapeutic class has been segmented into diuretics, Angiotensin-converting enzyme (ACE) inhibitors, Angiotensin II receptor blockers (ARBs), calcium channel blockers, beta-adrenergic blockers, renin inhibitors, vasodilators, and others. The diuretics segment accounted for the largest market share of 28% in 2017, with a market value of USD 9920.6 million, which is projected to register a CAGR of 2.85% during the forecast period.
The market based on type has been segmented into primary hypertension and secondary hypertension. The primary hypertension segment accounted for the largest market share of 86% in 2017, with a market value of USD 30,075.6 million, which is projected to register a CAGR of 2.53% during the forecast period.
Global antihypertensive drugs market, on the basis of distribution channel, has been segmented into retail pharmacy, online pharmacy, E-commerce websites and online drug stores, and others. The retail pharmacy segment accounted for the largest market share of 45% in 2017, with a market value of USD 15,805.7 million in 2017, which is projected to register a CAGR of 2.67% over the assessment period.
The Antihypertensive Drugs Market market is projected to grow at a CAGR of 3.1% from 2015 to 2023.
Historical performance and future projections (2020–2030, USD Billion)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansMarket Size (USD Mn)
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansHypertension is also known as high blood pressure. It is a long-term medical condition in which the blood pressure in the arteries is persistently elevated. Hypertension can lead to various severe problems such as renal impairment, visual impairment, retinal hemorrhage, and heart failure. Factors such as increase in the prevalence rate of high blood pressure, changing environmental factors, and rise in the use of combination therapies are expected to boost the growth of the market.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThis report applies a rigorous multi-stage research process combining primary interviews, secondary data sources, and bottom-up market modelling to ensure accuracy and completeness across all segments and geographies.
Base Year
2017
Historical Period
2015 – 2017
Forecast Period
2017 – 2023
Primary Interviews
150+
Historical data (2015–2017) and forecast period (2017–2023)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansMichael Porter's five forces model gives a framework that models the global antihypertensive drugs market which is influenced by five forces. The strategic business manager trying to create an edge over competitive firms in the global antihypertensive drugs market and can utilize this model to comprehend better the industry connection in which the firm operates. The components of each of the forces and the degree of impact of each component in the context of the global antihypertensive drugs market industry have been broken down and analyzed.
Market estimates by geography (2023)
InsightAmericas leads with $15.32B by 2023, while Asia Pacific is projected to grow fastest at a 3.5% CAGR.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2015 | 2017 | 2023 | CAGR | SHARE |
|---|---|---|---|---|---|
| Europe | $9.04B | $10.46B | $11.27B | 2.8% | 27% |
| Asia Pacific | $7.47B | $8.47B | $9.86B | 3.5% | 24% |
| Middle East and Africa | $3.99B | $4.56B | $4.67B | 2.0% | 11% |
| Americas | $11.72B | $13.70B | $15.32B | 3.4% | 37% |
| Total | $32.21B | $37.18B | $41.12B | 3.1% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansTotal Market Size
$41.12B
| APPLICATION | REVENUE ($B) | GROWTH RATE | MARKET PENETRATION |
|---|---|---|---|
| Primary Hypertension | $35.29B | 3.1% | 85% |
| Secondary Hypertension | $5.83B | 3.1% | 40% |
* Revenue projections based on 2025 estimates. Growth rates represent CAGR 2024–2030. Market penetration indicates current adoption rate within addressable market segments.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.

Analytical insights on Antihypertensive Drugs Market covering market dynamics, competitive landscape, and strategic outlook.
The Antihypertensive Drugs Market market is projected to reach $41.12B by 2023, growing at 3.1% CAGR. The Primary Hypertension segment holds the largest share.
High blood pressure is a common condition in which the long-term force of the blood against the artery walls is high enough that it may eventually cause serious health problems, such as various coronary problems. Factors such as the rising prevalence of hypertension, increasing initiatives by public and private organizations, the rise in the prevalence rate of chronic diseases, and increasing penetration of generic versions of drugs are major drivers propelling the market growth.
Over the past years, the prevalence of hypertension has been increasing, and this accounts to fuel the growth of the global antihypertensive drugs market. For instance, according to the data published by the World Health Organization (WHO) in 2017, the global prevalence rate of raised blood pressure in adults aged more than 18 was estimated to be 22.1% in 2015. Thus, the increasing prevalence of the disorder is expected to provide favorable backgrounds for the market to grow over the forecast period.
Clinical evidence suggests that there are emerging therapies that have fewer side-effects of traditional drugs used currently and are cost effective as well. This displays higher response rates for emerging therapies among patients. For instance, according to the data published by the National Center for Biotechnology Information in 2017, preclinical studies in 2015 showed that centrally administered Ang III (Angiotensin) was more effective to normalize blood pressure than Ang II.
Moreover, there have been preclinical trials in which a minimally invasive catheter-based radiofrequency strategy was used to cause renal nerve denervation in an attempt to lower blood pressure in patients with Treatment-Resistant Hypertension (TRH). Also, several companies have drugs for hypertension in clinical trials. For instance, Esaxerenone, a drug by Daiichi Sankyo Company, Ltd, for the treatment of hypertension, essential hypertension, hyperaldosteronism, and diabetic nephropathies was in Phase III of clinical trials in 2016. In September 2017, the company announced the positive results of Esaxerenone for the treatment of essential hypertension from Phase 3 study in Japan. Thus, the increase in novel therapies for the treatment of high blood pressure is estimated to contribute to the market growth over the next couple of years.
The treatment options for hypertension include antihypertensive therapeutic class drugs such as diuretics, angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers (ARB), calcium channel blockers, beta-adrenergic blockers, renin inhibitors, vasodilators, and others. Although diuretics are the first line of treatment, the side-effects of these include impotence, lethargy, nausea, and hypovolemia. ACE inhibitors are also an effective class of drugs but have side effects and adverse drug reactions such as elevated blood potassium levels, dizziness, drowsiness, diarrhea, and low blood pressure. Thus, the increase in side-effects and adverse events caused by treatment options are projected to hamper the growth of the market.
Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.
Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.
Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.
Profiles of 107 companies operating in the Antihypertensive Drugs Market market, including revenue, employee count, and market positioning where available.
Showing 107 of 107 companies
Takeda Pharmaceutical Company Limited
Company Headquarters: Japan Founded: 1925 Workforce: ~ 47,347 Company Working: Takeda Pharmaceutical Company Limited is a Japan-based company mainly engaged in the pharmaceutical business. The Company is engaged in the research, development, manufacture and sale of pharmaceutical products, General medical products, quasi drugs, and healthcare products in Japan and overseas. The Company's research and development functions are concentrated in four areas of oncology (cancer), digestive system diseases, rare diseases, and neurology (neuropsychiatric diseases), as well as two business units of plasma fractionation products and vaccines. The Company is engaged in the improvement of pipelines at research and development centers located mainly in Japan and the United States.
AstraZeneca
Company Headquarters: Cambridge, UK Founded: 1999 Workforce: 83,100 Company Working: AstraZeneca is a leading biopharmaceutical company. It focuses on developing and commercializing prescribed medicines. It has three main therapy areas, namely, cardiovascular, and metabolic disease (CVMD), oncology, and respiratory. It is also active in areas such as neuroscience autoimmunity and infection. It has more than 164 projects in its pipeline, nine new molecular entities in its late-stage pipeline, and one new molecular entity approval in the last quarter of 2019. Its product portfolio includes medications in the field of oncology, cardiovascular, renal & metabolism, and respiratory diseases, among others. Geographically the company operates in more than 100 countries by offering its healthcare products to millions of people across the globe.
Boehringer Ingelheim International GmbH
Company Headquarters: Ingelheim am Rhein, Germany Founded: 1885 Workforce: ~50,370 Company Working: Boehringer Ingelheim International GmbH (Boehringer Ingelheim) has more than 100 years of legacy. Boehringer Ingelheim has three main business units, which include prescription medicine, animal health, and biopharma. The main focus of the company is to cure diseases with the help of its core R&D expertise. It constantly works to create solutions that go beyond treating the illness to have a positive impact on patients’ lives, on societies, and on science itself. Geographically it has its presence in Africa, Asia, Australasia, Europe, North America, and South America.
Merck KGaA
Company Headquarters: Darmstadt, Germany Founded: 1668 Workforce: ~60,348 Company Working: Merck KGaA (Merck) is a pharmaceutical company that offers a varied range of products subgrouped into three segments—healthcare, life sciences, and performance materials. The company delivers innovative health solutions and is dedicated to providing breakthrough solutions and technologies. The company research drugs in the areas of oncology and neurodegenerative as well as autoimmune and inflammatory diseases. It also markets cardiovascular, fertility, endocrinology, and over-the-counter products as well as products for industries such as pharmaceuticals, food, cosmetics, packaging, and coatings. It has expanded its global footprint through several mergers and acquisitions, such as the acquisition of Millipore and Sigma-Aldrich. The company is distributing its products in the following countries: China, India, Japan, Australia, Israel, United Arab Emirates, South Korea, Denmark, Italy, Netherlands, Spain, United Kingdom, Switzerland, Sweden, Argentina, Brazil, Canada, US, New Zealand among others.
SANOFI
Sanofi is a UK-based global life sciences company which was incorporated in the year 2004. Sanofi is headquartered in Paris having the employee strength of more than 110,000 spread in more than 100 countries and have industrial sites in more than 40 countries. The company is committed to improve the access to healthcare and support the people to whom it serves throughout the continuum of care. Further, the company has its offerings into healthcare solutions, human vaccines, rare diseases, multiple sclerosis, oncology, immunology, infectious diseases, diabetes and cardiovascular solutions, and consumer healthcare. Sanofi CEPiA is a subsidiary business unit of Sanofi that produces articaine hydrochloride in API form. It is a market leader in producing articaine hydrochloride. The company manufactures articaine hydrochloride in its high capacity FDA approved workshop. Sanofi’s Ankleshwar production plant has an export sales of Rs. 54,900 lakhs that is around 27% of their total sales in India in 2015 . Their healthcare solutions are available in more than 170 countries across the world and now Sanofi is focussing on increasing its presence in emerging countries. Their industrial network, know-how and employees deliver a wide range of health solutions to millions of individuals with high quality and safety. Some of the top competitors of Sanofi are Pfizer Inc., Merck & Co., Inc. GlaxoSmithKline Plc., Septodont, Dentsply Sirona, and Pierrel S.p.A., among others.
Novartis AG
Company Headquarters: Basel, Switzerland Founded: 1996 Workforce: ~126,000 Company Working: Novartis AG (Novartis) was established in 1996 through a merger of Ciba-Geigy and Sandoz. Novartis and its preceding companies have been known to develop innovative products which can be traced back to over 250 years. The company focuses on the development and marketing of products that contribute to human progress through advances in science and health. It provides products that find applications in cancer, cardio-metabolic, immunology and dermatology, ophthalmology, neuroscience, and respiratory disease areas. Its Sandoz segment offers active ingredients and finished dosage forms of pharmaceuticals in cardiovascular, dermatology, central nervous system (CNS), gastrointestinal and hormonal therapy, metabolism, oncology, ophthalmic, pain, and respiratory areas, among others. It also provides active pharmaceutical ingredients (API) and intermediates primarily antibiotics, protein- or other biotechnology-based products including biosimilars, and biotechnology manufacturing services.
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Antihypertensive Drugs Market